| ¿µ¹® | adverse effect | ÇÑ±Û | ¿ªÈ¿°ú, À¯ÇØÈ¿°ú |
|---|---|---|---|
| ¼³¸í | ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇÏ´Â Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, ƯÈ÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀÎ ¿ªÈ¿°ú·Î¼ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù. |
||
| ¿µ¹® | vaccinia | ÇÑ±Û | ¿ìµÎ |
|---|---|---|---|
| ¼³¸í | 1. ¸¶¸¶ ¹é½ÅÀÇ Á¢Á¾À¸·Î ³ªÅ¸³ª´Â ÇǺΠ¹ÝÀÀÀ¸·Î¼ ¶§¶§·Î Àü½ÅÀûÀÎ ¹ÝÀÀÀ¸·Îµµ ³ªÅ¸³´Ù. 2. ¿øÄ¢ÀûÀ¸·Î ¼ÒÀÇ ¹ßÁø¼º¹ÙÀÌ·¯½ºº´ÀÌ´Ù. »ç¶÷¿¡°Ô´Â ¿ìµÎ¹ÙÀÌ·¯½ºÀÇ Á¢Á¾À¸·Î ±¹¼Ò ³óÆ÷¼º ¹ßÁøÀÌ »ý±â¸ç, ¿ìµÎ¸¦ ¾ÎÀº Áö ¾ó¸¶ ¾ÈµÇ´Â ¼ÒÀÇ ¿ìÀ¯¸¦ § »ç¶÷, º´µç ¼Ò, ¿ì»çéÚÞì¿¡ ±ñ ¤ µî¿¡¼ °¨¿°ÇÑ´Ù. Áø´ÜÀº ÀÓ»óÁõ¼¼ºÎÅÍ »ìÇÉ´Ù. ȯºÎÀÇ ¼Òµ¶ÀÌ ÃæºÐÇÏ¸é º´ÅÍ´Â 10~15ÀÏ ¸¸¿¡ ³´´Â´Ù. »ç¶÷ÀÇ Á¾µÎ¿¡´Â ÀÌ º´¿øÃ¼°¡ ¾²ÀδÙ. Á¢Á¾ ÈÄ¿¡´Â ¿ìµÎ¹ÙÀÌ·¯½ºÀÇ °¨¿°, ¼¼±Õ¿¡ ÀÇÇÑ ÀÌÂ÷ °¨¿° ȤÀº °¨¿° ÈÄ ¼ö¸·³ú¿° µîÀÇ ±¹¼Ò ȤÀº Àü½Å ÇÕº´ÁõÀÌ ÀÚÁÖ »ý±ä´Ù. |
||
| ¿µ¹® | immunological reaction | ÇÑ±Û | ¸é¿ª¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | »ýüÀÇ ¸ö ¾È¿¡¼ »ý±ä ¹°ÁúÀ̳ª ¸ö ¹Û¿¡¼ µé¾î¿Â ¹°ÁúÀÌ »ýü¿Í ´Ù¸¦ ¶§ ÀÚ±â ü³»ÀÇ ÅëÀϼº°ú °³Ã¼ÀÇ »ýÁ¸ À¯Áö ¹× Á¾ÀÇ Á¸¼ÓÀ» À§ÇÏ¿© ±× ¹°ÁúµéÀ» Á¦°ÅÇÏ´Â ÀÏ·ÃÀÇ »ýü ¹ÝÀÀ. ´Ù½Ã ¸»ÇØ B¼¼Æ÷¿¡ ÀÇÇÑ Ç×ü»ý»ê, T¼¼Æ÷¸¦ Áß½ÉÀ¸·Î ÇÏ´Â ¼¼Æ÷¼º ¸é¿ª, ¸é¿ª°ü¿ë, ¸é¿ª±â¾ï µîÀÇ »ýü ³» ¹ÝÀÀÀ» ¸»ÇÑ´Ù. Å«Æ÷½Ä¼¼Æ÷´Â Ç׿øÀ» ó¸®Çؼ ƯÀÌÀûÀÎ Ç׿ø°áÁ¤±â¸¦ °®´Â ºÐÀÚ·Î ¹Ù²ã, Ç׿ø°ú ÁÖ¿äÁ¶Á÷ ÀûÇÕÀ¯ÀüÀÚº¹ÇÕü¸¦ ¼¼Æ÷Ç¥¸é¿¡ Ç¥ÇöÇϸç, T¼¼Æ÷·Î Àü´ÞÇÑ´Ù. ÇÑÆí B¼¼Æ÷´Â Å«Æ÷½Ä¼¼Æ÷ ³»¿¡¼ ó¸®µÈ Ç׿øÀÇ °áÁ¤±â¸¦ ÀνÄÇÏ¿© ´ëÀÀÇϴ ƯÀÌÀûÇ×ü¸¦ »ý»êÇÏ¿© Ç׿øÀ» ó¸®ÇÑ´Ù. |
||
| ¿µ¹® | reaction formation | ÇÑ±Û | ¹Ýµ¿Çü¼º, ¹ÝÀÀÇü¼º |
|---|---|---|---|
| ¼³¸í | ¾ï¾Ðº¸´Ù ´õ Àû±ØÀûÀÎ ¹æ¾î¸ÞÄ¿´ÏÁòÀ̸ç, ¹«ÀǽÄÀûÀÎ »ý°¢, ¼Ò¿ø, Ãæµ¿ÀÌ ³Ê¹«³ªµµ ¹Þ¾Æµé¿©Áú ¼ö ¾ø´Â °ÍÀÏ °æ¿ì¿¡ À̿ʹ Á¤¹Ý´ë ¹æÇâÀÇ °ÍÀ» °Á¶ÇÔÀ¸·Î½á ±×·± ¹«ÀǽÄÀûÀÎ °ÍµéÀÌ ÀǽĵÇÁö ¾Ê°Ô ÇÏ´Â °úÁ¤. ¿¹¸¦ µé¸é °¡Àå °¡ÇÐÀûÀÎ ¼º°ÝÀÇ »ç¶÷ÀÌ »ýÃ¼ÇØºÎ ¹Ý´ë·ÐÀÚ°¡ µÇ´Â °æ¿ì¸¦ µé ¼ö ÀÖ´Ù. À̰ÍÀº ¶Ç °¡½¿ ±íÀÌ Àá°ÜÀÖ´Â µÎ·Á¿òÀÌ ÀǽĵǴ °ÍÀ» ÇÇÇϱâ À§Çؼ µÎ·Á¿òÀÇ ´ë»óÀÌ µÇ´Â Çൿ¿¡ °ñ¸ôÇÏ´Â °æ¿ìµµ Æ÷ÇÔÀÌ µÈ´Ù. ¿¹¸¦ µé¸é, ³²ÀÚ¿¡°Ô »óó¹ÞÁö ¾ÊÀ»±î ÇÏ´Â µÎ·Á¿ò¿¡ °¡µæ Âù ¼Ò³à°¡ ÀÌ °°Àº µÎ·Á¿òÀ» ºÎÁ¤ÇÏ·Á´Â ¼ö´ÜÀ¸·Î ³ÀâÇÑ ¼ºÇàÀ§¿¡ °ñ¸ôÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¶Ç ÀüóÀÇ Àڳฦ ¹Ì¿öÇÏ´Â °è¸ð°¡ ¿ÀÈ÷·Á Áö³ªÄ¥ Á¤µµ·Î ±× ¾ÆÀ̸¦ ±Í¿©¿öÇÏ´Â ÀÏ µûÀ§ÀÌ´Ù. |
||
| ¿µ¹® | complement fixation reaction | ÇÑ±Û | º¸Ã¼°áÇÕ ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | Ç×ü¿ÍÀÇ ¹ÝÀÀ¿¡ ÀÖ¾î¼ º¸Ã¼¿Í °áÇÕÇÏ´Â Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀ¸·Î, ÀÌ ¹ÝÀÀÀº ÃÖÃÊ¿¡ ±âÁöÇ׿ø, ÇǰËÇ÷û ¹× º¸Ã¼¸¦ È¥ÇÕÇÑ´Ù. Á¦2´Ü°è¿¡¼´Â ÀûÇ÷±¸¿Í À̰Ϳ¡ ´ëÀÀÇÏ´Â ¿ëÇ÷¼ÒÀÇ È¥ÇÕ¾×À» °¡ÇÑ´Ù. º» ¹ÝÀÀÈÄ ¿ëÇ÷ÀÌ ÀϾÁö ¾ÊÀ¸¸é º»Ã¼´Â Ç׿øÇ×ü°áÇÕ¹°¿¡ °áÇÕÇÑ °ÍÀÌ µÇ¾î ¾ç¼ºÀÌ µÇÁö¸¸, ¿ëÇ÷ÀÌ ÀÏ¾î³ °æ¿ì º¸Ã¼´Â °áÇÕÇÏÁö ¾Ê¾Æ ¼ÒºñµÇÁö ¾Ê±â ¶§¹®¿¡ À½¼ºÀÌ µÈ´Ù. º» ¹ÝÀÀÀº ±âÁöÇ÷ûÀ» ½á¼ Ç׿ø°ËÃâ¿¡ ÀÀ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ¸¶ÀÌÄÚÇö󽺸¶, ¸®ÄÉÃ, Ŭ¶ó¹Ìµð¾Æ, ¹ÙÀÌ·¯½º, ¸Åµ¶ µîÀÇ Áø´Ü¿¡ ¾²ÀδÙ. |
||
| ADR | activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ... |
|---|---|
| ARMS | adverse reaction monitoring system; amplification refractory mutation system |
| SADR | suspected adverse drug reaction |
| VIG, VIg | vaccinia immunoglobulin |
| VV | vaccinia virus; varicose veins; veno-venous; viper venom; vulva and vagina |
| ADR | Adverse Drug Reaction |
|---|---|
| MVA | Modified Vaccinia Ankara |
| MVA | Modified Vaccinia Virus Ankara |
| RVV | Recombinant vaccinia virus |
| VMO | Vaccinia Melanoma Oncolysates |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
|---|---|
| adverse reaction | Any undesirable or unwanted consequence of a preventive, diagnostic, or therapeutic procedure or regimen. (05 Mar 2000) |
| adverse | Harmful. (18 Nov 1997) |
| adverse effect | This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical. (09 Oct 1997) |
| adverse event | A toxic reaction to a medical therapy. (09 Oct 1997) |
| bovine vaccinia mammillitis | A poxlike disease of the skin of the bovine teat caused by vaccinia virus. (05 Mar 2000) |
| vaccinia | <dermatology> The cutaneous and sometimes systemic reactions associated with vaccination with smallpox vaccine. (18 Nov 1997) |
| vaccinia gangrenosa | A severe or even fatal form of vaccinia occurring chiefly in subjects with an immunologic deficiency or dyscrasia and characterised by progressive enlargement of the initial and also of secondary lesions. Synonym: vaccinia gangrenosa. (05 Mar 2000) |
| vaccinia virus | <molecular biology, virology> DNA viruses used in several biotechnology applications, including expression vector systems. Because they can hold quite a lot of DNA, they can be used to make more than one protein at once in a cell, which can be useful for making proteins with more than one polypeptide chain. (14 Nov 1997) |
| variola vaccinia | <dermatology> The cutaneous and sometimes systemic reactions associated with vaccination with smallpox vaccine. (18 Nov 1997) |
| generalised vaccinia | Secondary lesions of the skin following vaccination which may occur in subjects with previously healthy skin but are more common in the case of traumatised skin, especially in the case of eczema (eczema vaccinatum). In the latter instance, generalised vaccinia may result from mere contact with a vaccinated person. Secondary vaccinial lesions may also occur following transfer of virus from the vaccination to another site by means of the fingers. (05 Mar 2000) |
| progressive vaccinia | A severe or even fatal form of vaccinia occurring chiefly in subjects with an immunologic deficiency or dyscrasia and characterised by progressive enlargement of the initial and also of secondary lesions. Synonym: vaccinia gangrenosa. (05 Mar 2000) |
| no-observed-adverse-effect level | The highest dosage administered that does not produce toxic effects. The noael will depend on how closely dosages are spaced (lowest-observed-adverse-effect level and no-observed-effect level) and the number of animals examined. The ultimate objective is usually to determine not the "safe" dosage in laboratory animals but the "safe" dosage for humans. Therefore, the extrapolation most often required of toxicologists is from high-dosage studies in laboratory animals to low doses in humans. (casarett and doull's toxicology: the basic science of poisons, 4th ed) (12 Dec 1998) |
| event, adverse | In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug. (12 Dec 1998) |
| accelerated reaction | A response occurring in a shorter time than expected; the cutaneous manifestations occurring during the period between the second and tenth day following smallpox vaccination; because it is intermediate between a primary reaction and an immediate reaction, it is regarded as evidence of some degree of resistance. Synonym: vaccinoid reaction. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|